MDL 3140 · U.S. District Court, Northern District of FloridaSettlement open
Used Depo-Provera and have a brain tumor? Ask a lawyer to check your shot dates, diagnosis and claim options.
Updated 16 sources
See If You Qualify
Free · No obligation · About 2 minutes
Updated 16 sources
This may apply to you if
The process
You answer a few questions
About two minutes. Nothing is sent until you agree on the last step and press submit.
A lawyer looks at it
A lawyer at the firm reads your answers and checks them against the current case criteria.
The firm decides and gets in touch
If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.
At a glance
Who qualifies
Lawsuits filed
Discovery
Bellwether trials
Now
Settlement
Payments
Closed
These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.
M. Casey Rodgers · U.S. District Court, Northern District of Florida · United States District Judge
Finding: The August 10, 2026 order describes an agreement for many existing federal claims and separate court procedures for continuing litigation. Ask a lawyer which track applies to you.
Case Management Order No. 14 (opens in a new tab) · Aug 10, 2026 · Checked Oct 3, 2026
Noémie Roland · EPI-PHARE, French National Agency for Medicines and Health Products Safety and French National Health Insurance · First-listed study author
Finding: The 2024 BMJ study found an association between injectable medroxyprogesterone use and meningioma surgery in French health records. A small exposed group and observational design limit what it can show about an individual.
Use of progestogens and the risk of intracranial meningioma: national case-control study (opens in a new tab) · Mar 27, 2024 · Checked Oct 3, 2026
EPI-PHARE · BMJ · 2024
Read the source: French health-record study of hormone medicines and meningioma surgery (opens in a new tab) · Checked Oct 3, 2026
An agreement offers many people with existing federal cases a way to resolve their claims. Ask your lawyer if it covers you. New claims need a separate check.
Not covered by this case
Check how the fee is worked out, which costs are separate, and whether you owe costs if the claim does not win. The ABA rule is a model; verify your state and agreement.
Source: ABA Model Rule 1.5: fees · as of Oct 3, 2026
List your shot dates and the clinic names. Keep the scan and diagnosis reports. Ask the provider how to request missing covered records.
Source: Medical record access: 45 CFR 164.524 · as of Oct 3, 2026
Ask your lawyer which court track and time limit apply. If you have no lawyer, ask whether the firm takes new claims before sharing private records.
Source: Court order 14: settlement and ongoing cases · as of Oct 3, 2026
Ask how the firm charges and what costs you might owe. Confirm who receives your health records and how staff will contact you.
Source: ABA Model Rule 1.5: fees · as of Oct 3, 2026
Settlement · Announced
Read the study: Medroxyprogesterone Acetate and Meningioma: A Global Issue (opens in a new tab)
Public agency records
Ingredient-level FDA records for medroxyprogesterone acetate, including other brands and formulations. FAERS reports that list MENINGIOMA or MENINGIOMA BENIGN and the generic name; reports may list multiple drugs and reactions, with no link between an individual drug and reaction.
FDA data updates: Jul 30, 2026; Oct 21, 2026. Queries refresh about once a day. Source data may lag reporting by three months or more. These records do not determine whether an individual has a legal claim.
Latest matching enforcement records, up to ten; recall dates are initiation dates. A match does not establish that a particular unit or lot was recalled. Check the product details in the FDA source.
Dec 18, 2024 · Status: Ongoing
medroxyPROGESTERone Acetate Injectable Suspension, USP, 150mg per mL, Rx only, 1 mL Single-Dose Vial, Mfd in India for: Eugia US LLC, NJ 08520 NDC 55150-329-01 Shipper label: medroxyPROGESTERone Acetate Injectable Suspension, USP, 150 mg per mL, Distributed by: Eugia US LLC, NJ, Manufactured by: Eugia Pharma Specialties Limited, India
Reason reported by FDA: CGMP Deviations
May 6, 2022 · Status: Terminated
medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Prefilled Syringe, 150 mg/mL, Rx only, Manufactured by Sun Pharmaceutical Industries Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, NDC 62756-091-40.
Reason reported by FDA: Lack of assurance of sterility
Twenty completed calendar quarters (five years), grouped by date received by FDA. Counts reflect matching reports, including possible follow-up or duplicate reports, and represent neither people nor confirmed injuries. A zero means no matches in the available API data; unavailable data is shown separately.
Each report must list a mapped generic name and at least one of these exact reaction terms. Reports may list multiple drugs and reactions; the data does not connect an individual drug to an individual reaction. Counts include other brands and formulations.
openFDA’s data limitations: “Therefore, a causal relationship cannot be established between product and reactions listed in a report.” Reports “cannot be used to estimate the incidence” of these events (FAERS disclaimer).
| Quarter | Reports | Limitations |
|---|---|---|
| 2026 Q3 | 0 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2026 Q2 | 8,508 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2026 Q1 | 1,381 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2025 Q4 | 368 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2025 Q3 | 839 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2025 Q2 | 539 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2025 Q1 | 81 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2024 Q4 | 93 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2024 Q3 | 4 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2024 Q2 | 4 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2024 Q1 | 0 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2023 Q4 | 1 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2023 Q3 | 3 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2023 Q2 | 0 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2023 Q1 | 1 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2022 Q4 | 0 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2022 Q3 | 0 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2022 Q2 | 7 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2022 Q1 | 0 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
| 2021 Q4 | 0 | Reports “cannot be used to estimate the incidence” of these events; a reported association does not establish causation. |
If you used the shot and have a meningioma, ask for a claim check. A meningioma is a tumor in tissue around the brain. Your shot dates and health records matter.
The federal cases concern people who say this type of tumor was caused by Depo-Provera or a generic version. That is what the claims allege. It does not show that the shot caused your own tumor. Bring the exact drug name and the report from the doctor who made the diagnosis.
Do not use an online rule about age, a set number of shots or a fixed gap between use and diagnosis to rule yourself in or out. No such universal screen has been verified for this page. Ask the firm to explain the rule it uses and whether that rule concerns a new claim or the reported program.
The court reports an agreement dated July 22, 2026 for many existing federal claims. Its order gives November 30, 2026 as the sign-up date. Ask your lawyer whether your claim is covered.
The October 1, 2026 court-panel report lists 6,412 pending federal cases. Pending means still in that court group on that date. It does not mean those people have been paid, that all are eligible for the deal, or that this is the total number of people harmed.
The order also sets out how other claims can proceed. Do not assume an agreement resolves every case or ends the chance to ask about a new one. If you already have a lawyer, speak with that lawyer about your own status and whether a later order changes it.
No one has announced a per-person payout in the public court order reviewed here. The order reports a deal, but not an award grid. Ask your own lawyer what terms apply to you.
Do not treat a dollar range on another page as your likely payment. Ask for a sourced offer rather than an estimate. Ask for the actual written offer, if one applies to you, and an explanation of any costs that come out before money reaches you.
The court has a separate order about shared legal-work fees. For claims it covers, that assessment comes from the lawyer’s fee portion. It does not replace your own fee agreement. Ask the firm to explain your fee and each deduction separately.
Ask for the firm’s fee terms in writing. Check the lawyer’s share, the case costs, and what you may owe if you do not win. No firm’s price has been verified here.
A fee tied to the result and case expenses are separate questions. The ABA model rule says the written terms should explain how the fee is worked out and whether expenses can still be owed after a loss. Your state’s rule and your signed agreement need their own review.
Before you sign, ask: Is there a charge for the first conversation? Are records or expert costs extra? Are costs taken out before or after the fee? What happens if the firm declines or ends the case? Request answers tied to this claim, rather than a general promise about all injury claims.
The order gives November 30, 2026 for program sign-up. The June 11, 2026 cutoff concerns a limited court track. Ask a lawyer to check which dates apply to your claim.
For that track, the order requires both program eligibility and a lawyer agreement signed by the June date. It also discusses people who file new claims later. The cutoff is not a statement that everyone who missed it has no case.
A filing time limit and a program sign-up date are different questions. The court guide says filing limits depend on the law and type of claim. Tell the lawyer where you lived, when you used the shot and when the tumor was found. Do not wait for this page to work out your deadline.
Save your shot dates and the report that names the tumor. Ask the clinic for missing records. Bring medicine questions to your doctor and claim questions to a lawyer.
Start with what you have: clinic names, medicine receipts, scan reports and treatment letters. Note which dates are clear and which you only recall. Ask the provider for the records rather than filling gaps with guesses. Keep your original files.
For covered medical records, the federal access rule generally requires a response within 30 days. It permits one extra period of up to 30 days with written reasons and a new date. Some records are excluded, and written requests may be required. Ask the provider about its process and any fee.
The FDA label reports meningiomas after repeated use, mainly long-term use. This is a safety warning. It does not decide what caused your tumor or whether a claim will win.
The revised label has a specific meningioma warning. It directs clinicians to monitor signs and stop the product if that tumor is diagnosed. Contact your treating clinician about what that means for your care. A claim page should not decide your medicine plan.
The National Cancer Institute explains where this tumor forms and how doctors assess it. A tumor diagnosis, proof of drug use and the question of legal responsibility are different pieces of the review. This package does not use an unverified study number to predict your personal risk.
Researchers at EPI-PHARE used French health records for a 2024 study in BMJ. Noémie Roland is its first-listed author. The study compared 18,061 women who had surgery for meningioma with 90,305 women matched by birth year and where they lived. It found a link between use of the injectable drug and this type of surgery. The excess risk was linked to longer use.
The study has important limits. It used records rather than assigning people to take a medicine at random. Only nine of the surgery cases and eleven of the matched controls had used the injection. A finding in that small group does not show that the shot caused a particular person’s tumor. It does not tell a lawyer who must be accepted for a claim. Ask your care team about health questions and a lawyer about the evidence needed for your own case.
Ask first whether the firm takes new Depo-Provera claims. Then ask who will see your records and how fees work. Ask the firm to explain its contact and privacy terms.
If a lawyer already represents you, ask that lawyer about program sign-up and your current case track. If you are asking for the first time, request a plain explanation of the firm’s screen before sending private health records. A published court agreement does not show that a particular firm will accept you.
Before sending information, ask for the firm’s identity, privacy terms and fee agreement. Ask who will see your answers, how to give consent and when to expect a reply. Confirm those terms before sending health records.
The answers below explain the reported deal and common record questions. They cannot decide your eligibility or time limit. Ask a lawyer for the rules that apply to your own claim.
The court order supports the program dates, and the court-panel report supports the dated case count. The FDA label supports the safety warning. Each source answers a different question.
Your state
Deadlines vary by state and by case. A lawyer can confirm yours.
The FDA label says meningiomas have been reported after repeated use of medroxyprogesterone acetate, mainly with long-term use. It tells clinicians to monitor patients for signs and symptoms of meningioma. It also says to discontinue Depo-Provera CI if a meningioma is diagnosed.
Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026
No. The public court order reviewed here does not give one shot-count rule for every person. It describes different groups in the MDL and a settlement program, so a lawyer needs to check which rules apply to your facts.
Source: Case Management Order No. 14, In re Depo-Provera MDL 3140 · as of Oct 7, 2026
Not necessarily. The court order uses June 11, 2026 for a limited administrative-docket path tied to the settlement program. It also defines future-filed plaintiffs separately, so a lawyer should check which deadline and track apply to you.
Source: Case Management Order No. 14, In re Depo-Provera MDL 3140 · as of Oct 7, 2026
No. The public order reviewed here does not announce a payment for each person. Ask your lawyer to review any written offer and do not use online estimates as your likely result.
Source: Case Management Order No. 14, In re Depo-Provera MDL 3140 · as of Oct 7, 2026
Keep the records you already have for the Depo-Provera review. Dates, product or account details, medical records, photos, receipts, and reports may help a lawyer understand what happened. Ask what else is needed before sending private material to anyone.
Source: HHS: Your Medical Records · as of Oct 7, 2026
No. Your treating clinician should help decide your next dose or a different birth control option. The FDA label says to monitor for meningioma signs and to discontinue Depo-Provera CI if a meningioma is diagnosed.
Source: FDA Depo-Provera CI label, revised December 2025 · as of Oct 7, 2026
Not necessarily. Case Management Order 14 says the settlement program has a registration deadline of November 30, 2026, and a limited administrative-docket path for eligible people who signed engagement letters by June 11, 2026. The same order also defines future-filed plaintiffs separately. A lawyer can check your state deadline and which MDL track applies.
Source: Case Management Order No. 14, In re Depo-Provera MDL 3140 · as of Oct 7, 2026
MDL 3140 is the federal court group for Depo-Provera meningioma product-liability cases. The JPML created it in February 2025 in the Northern District of Florida before Judge M. Casey Rodgers. A later court order describes a settlement program, but it does not state payment amounts.
Source: Case Management Order No. 14, In re Depo-Provera MDL 3140 · as of Oct 7, 2026
Checked against 14 primary sources by People's Justice editors · Updated
How we make moneyThe review is free and private. Asking for it doesn’t commit you to anything.
Register your interest